Web Analytics

3 Latest Announced Rounds

  • $3,500,000
    Seed

    1 Investors

    Technology, Information and Internet
    Dec 20th, 2024
  • $5,619,170
    Series B

    1 Investors

    Research Services
    Dec 20th, 2024
  • $8,000,000
    Unknown

    5 Investors

    Computer & Network Security
    Dec 20th, 2024
$671.88M Raised in 44 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Laerdal Million Lives Fund

investor
United States - San Francisco, CA
  • 09/12/2022
  • Series A
  • $15,100,000

The Laerdal Million Lives Fund is committed to investing in, partnering with and supporting entrepreneurs who are developing and deploying new emerging technologies capable of saving lives across the globe. We target investments in commercial stage technologies that (i) address mortality rates across clinical areas, such as maternal, neonatal, emergency medicine, critical care, surgery and others, and (ii) provide better medical education and training to providers and patients. We prioritize investments that can meaningful impact mortality rates at a global scale by improving healthcare quality and outcomes regardless of demographic or geography, thus contributing directly to our global goal of saving 1 million lives annually by 2030.


Related People

Jeff TrostInvestor

Jeff Trost United States - San Francisco, California

Jeff Trost is the managing partner of the Laerdal Million Lives Fund, investing in global health technologies that contribute directly to saving lives. He is also the founding managing director of Greenbox Venture Partners, an early-stage healthcare technology venture capital fund, and is currently working with Rock Health's venture fund.

Previously, Jeff was the Director of healthcare investment banking at GCA Savvian, where he spent nearly 12 years working with clients across a number of healthcare industries, including diagnostic and therapeutic imaging modalities, connected and remote patient monitoring devices, surgical equipment, digital health solutions and orthopedic / biologic products. In these healthcare sub-sectors, he has worked with and advised venture-backed, private equity and multi-national public companies on fundraising, M&A, joint ventures, partnering and other strategic transactions. In particular, Jeff has significant experience with cross-border M&A transactions between Japan / Asia Pacific and the US, having advised many Asian buyers on their investment and acquisition strategies in the US.

Select transactions include:
Santen Pharmaceutical's acquisition of InnFocus (Japan / US M&A)
Signostic's capital raise / partnership with KKR
Pathfinder Technologies acquired by Analogic Corporation
BioServe acquired by ReproCell (Japan / US M&A)
Medicine360 licensing agreement with Actavis
Nihon Kohden's acquisition of Defibtech (Japan / US M&A)
SonoSite acquired by FujiFilm (Japan / US M&A)
Olympus' acquisition of Stryker's OP-1 biologic / bone assets (Japan / US M&A)
SonoSite's acquisitions of VisualSonics and CardioDynamics

Prior to joining GCA Savvian, Jeff was a technology consultant with Accenture in their telecommunications group. Jeff received a BS in Biomedical Engineering, Electrical Engineering and Economics from Duke University.